NASDAQ:ADGI
Delisted

Adagio Therapeutics Stock Signals

etoro logo Buy ADGI
*Your capital is at risk
$2.47
+0.0900 (+3.78%)
At Close: Jan 27, 2023

Latest Data & Signals Issued

Below are some of the latest signals issued for Adagio Therapeutics, Inc.

General

Signal Type Signal Value Data
Score 0.000 92 days ( 46.77 %
Last Price $2.47 3.78 %
Performance History
7 Days
$1.81 $2.47
36.46%
30 Days
$3.29 $2.47
-24.92%
12 Mos
$6.59 $2.47
-62.52%

8/18

Active Buy Signals

Specific Signals

Short Term
Net score: 24.36
Signal Type Signal Value Importance Data
High / Low Buy Very Low $2.35 - $2.68
Position: 36.36% from low / 63.64% from high · Momentum: 15.79%
Trend - 3 mos -32.44 % High Width: 94.47 %
Pred. range - 3 mos $0.92 - $1.80 Low -62.61 % - -27.29 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Jan 20, 2023 - 6 days
RSI Short Pivot Signal Buy Very Low Jan 26, 2023 - 2 days
Short MA 3 mos Buy Low Jan 20, 2023 - 6 days
Long MA 3 mos Sell Medium Nov 17, 2022 - 48 days
Short/Long MA 3 mos Sell Medium Nov 17, 2022 - 48 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 42.91
Signal Type Signal Value Importance Data
Trend - 12 mos -25.74 % Very High Width: 1,356.63 %
Pred. range - 12 mos $0.411 - $5.99 High -83.36 % - 142.45 %
Short MA 12 mos Buy Very High Jan 23, 2023 - 5 days
Long MA 12 mos Sell Very High Sep 16, 2022 - 92 days
Short/Long MA 12 mos Sell Very High Sep 28, 2022 - 84 days
Pivot Long Buy Low Jan 20, 2023 - 6 days
RSI Long Pivot Signal Buy Low Jan 26, 2023 - 2 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Buy High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT ADAGIO THERAPEUTICS, INC.
Adagio Therapeutics
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with A...
GOLDEN STAR
Ticker Change Signal Date
N
NXDR
$2.27
7.93% Aug 03
MC
$67.08
3.53% Jul 31
FCX
$62.63
10.79% Jul 31
ARW
$212.85
6.58% Jul 30
BIIB
$202.19
2.20% Jul 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE